Terms: = Breast cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
250 results:
1. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract] [Full Text] [Related]
2. Synergy between PEDF and Doxorubicin in breast cancer Cells: Effects on Metastatic and Metabolic Pathways.
Abooshahab R; Al-Salami H; Dass CR
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474001
[TBL] [Abstract] [Full Text] [Related]
3. Unlocking the Power of the Homing Phenomenon: Why breast Conserving Surgery Outshines Mastectomy in Overall Survival.
Mokbel K
Clin Breast Cancer; 2024 Feb; 24(2):85-92. PubMed ID: 37925361
[TBL] [Abstract] [Full Text] [Related]
4. Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells.
Sharifhoseini A; Heshmati M; Soltani A; Entezam M; Shirzad H; Sedehi M; Judd BA; Jami MS; Ghatrehsamani M
Mol Biol Rep; 2023 Oct; 50(10):8319-8328. PubMed ID: 37589934
[TBL] [Abstract] [Full Text] [Related]
5. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of cxcr4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract] [Full Text] [Related]
6. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
7. cxcr4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/cxcr4 signaling axis in preclinical breast cancer model.
Gupta N; Mohan CD; Shanmugam MK; Jung YY; Chinnathambi A; Alharbi SA; Ashrafizadeh M; Mahale M; Bender A; Kumar AP; Putti TC; Rangappa KS; Zhang X; Ahn KS; Sethi G
Environ Res; 2023 Sep; 232():116335. PubMed ID: 37290620
[TBL] [Abstract] [Full Text] [Related]
8. Targeting cxcr4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S; Xie SM; Liu W; Gagea M; Hanker AB; Nguyen N; Singareeka Raghavendra A; Yang-Kolodji G; Chu F; Neelapu SS; Marchese A; Hanash S; Zimmermann J; Arteaga CL; Tripathy D
Breast Cancer Res; 2023 Jun; 25(1):62. PubMed ID: 37280713
[TBL] [Abstract] [Full Text] [Related]
9. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept.
Khaparkhuntikar K; Maji I; Gupta SK; Mahajan S; Aalhate M; Sriram A; Gupta U; Guru SK; Kulkarni P; Singh PK
J Biomol Struct Dyn; 2024; 42(3):1469-1484. PubMed ID: 37272883
[TBL] [Abstract] [Full Text] [Related]
10. Forkhead Box Q1 is a novel regulator of autophagy in breast cancer cells.
Kim SH; Hahm ER; Singh SV
Mol Carcinog; 2023 Oct; 62(10):1449-1459. PubMed ID: 37265428
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling.
Pascetta SA; Kirsh SM; Cameron M; Uniacke J
BMC Cancer; 2023 Jun; 23(1):494. PubMed ID: 37264315
[TBL] [Abstract] [Full Text] [Related]
12. TCF12 regulates exosome release from epirubicin-treated CAFs to promote ER+ breast cancer cell chemoresistance.
Qiu Y; Wang X; Sun Y; Du YE; Yin G; Luo H; Wen S; Lang L; Liu M; Tang X
Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166727. PubMed ID: 37137433
[TBL] [Abstract] [Full Text] [Related]
13. A Multiple Targeting Nanoprobe for Identifying cancer Metastatic Sites Based on Detection of Various mRNAs in Circulating Tumor Cells.
Han D; Ren XH; Liao XR; He XY; Guo T; Chen XS; Pang X; Cheng SX
Nano Lett; 2023 May; 23(9):3678-3686. PubMed ID: 37052638
[TBL] [Abstract] [Full Text] [Related]
14. CXC Chemokine Receptor Type 4 Antagonistic Gold Nanorods Induce Specific Immune Responses and Long-Term Immune Memory to Combat Triple-Negative breast cancer.
Meng Y; Zhou J; Liu X; Zeng F; Wen T; Meng J; Liu J; Xu H
ACS Appl Mater Interfaces; 2023 Apr; 15(15):18734-18746. PubMed ID: 37017641
[TBL] [Abstract] [Full Text] [Related]
15. breast cancer patient experiences of perioperative distress and anxiety: A qualitative study.
Grocott B; Reynolds K; Logan G; Hebbard P; El-Gabalawy R
Eur J Oncol Nurs; 2023 Apr; 63():102299. PubMed ID: 36893576
[TBL] [Abstract] [Full Text] [Related]
16. NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in breast cancer.
Brook N; Gill J; Dharmarajan A; Chan A; Dass CR
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555293
[TBL] [Abstract] [Full Text] [Related]
17. Exosomal miR-655-3p inhibits growth, and invasion and macrophage M2 polarization through targeting cxcr4 in papillary thyroid carcinoma.
Qiao L; Dong C; Jia W; Ma B
Acta Biochim Pol; 2022 Dec; 69(4):773-779. PubMed ID: 36512648
[TBL] [Abstract] [Full Text] [Related]
18. SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.
Wang RX; Ji P; Gong Y; Shao ZM; Chen S
Front Immunol; 2022; 13():940635. PubMed ID: 36341391
[TBL] [Abstract] [Full Text] [Related]
19. cxcr4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Xie XF; Wu NQ; Wu JF; Zhang GL; Guo JF; Chen XL; Du CW
Cancer Lett; 2022 Dec; 551():215944. PubMed ID: 36209974
[TBL] [Abstract] [Full Text] [Related]
20. Potential role of cxcr4 in trastuzumab resistance in breast cancer patients.
Kotb RM; Ibrahim SS; Mostafa OM; Shahin NN
Biochim Biophys Acta Mol Basis Dis; 2022 Nov; 1868(11):166520. PubMed ID: 35985446
[TBL] [Abstract] [Full Text] [Related]
[Next]
